



Connecting the Leaders of CNS for Improved Patient Success

June 15th - 16th | Virtual | ET Time

The current treatment of CNS disorders is leaving a lot of unmet medical needs for patients suffering from these conditions. Over the past few years, there have been minimal advancements in drug development and it's becoming clear that in order to deliver for patients, it will need a convergence of all stakeholders to provide more end-to-end treatment options.

The inaugural **CNS Leaders Forum** is designed to provide the platform for leaders from every corner of the industry to learn, share and collaborate in order to create a streamlined, patient-centric approach in tackling CNS disorders.

Constructed by the pioneers of the industry, this meeting is set to mould the future of CNS therapeutics development and position patients central in our endeavours.

Confirmed and Invited Speakers for The CNS Leaders Forum 2021

- **Kate Rosenbluth**, Co-Founder & CSO, **Cala Health**
- **Paulo Barbarino**, Chief Executive Officer, **Alzheimer's Disease International**
- **Mikael Eliasson**, Global Head of Innovation, Neuroscience, **Genentech**
- **Donna Walsh**, Executive Director, **European Federation of Neurological Associations**
- **Christoph Koch**, Chief Business Development Officer, **Neuraxpharm**
- **Mads Dalsgaard**, SVP, Head of Experimental Medicine & Clinical Development, **Lundbeck**
- **Ray Dorsey**, Professor of Neurology, Director, CHET, **University of Rochester Medical Center**

Conference Day 1, Tuesday, 15th June

8:00am **Conference Platform Opens**

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

9:00am **Chair's Opening Remarks and Setting the Scene**

Magdalene Moran, President & Chief Scientific Officer, **Caraway Therapeutics**

9:05am **Keynote Presentation: What does the Future Look Like for Patients with CNS Disorders?**

- What are the current efforts for treatment of CNS disorders?
- What key challenges are we facing as an industry that is stalling progress?
- How can we work together within the Neuroscience industry to advance patient treatment on the front line?

Innes Meldrum, SVP & Chief Commercial Officer, **Otsuka Pharmaceutical North America**

9:30am **Wellness Break**

Get-up and have a stretch before the next session begins.

9:35am **Panel Discussion: How Much is our Understanding of Fundamental Biology Impacting the CNS Treatment?**

- How are therapeutic development efforts being limited by our understanding of the fundamental biology of the central nervous system?
- What are some specific gaps within our knowledge that are preventing us from discovering more about CNS Diseases?
- How can we implement new technology, such as AI or ML, to aid in CNS research?

- What changes need to be made in clinical trials to help streamline efforts towards more effective results?
- Where do we hope the research is in 5 years time?

Newton Howard, Professor of Computational Neuroscience & Neurosurgery, **Nuffield Department of Scientific Surgery, University of Oxford**

Tiago Fleming Outeiro, Director of the Department of Experimental Neurodegeneration, **University Medical Center Gottingen**

Ray Dorsey, Professor of Neurology, Director, CHET, **University of Rochester Medical Center**

Natasha Hussein, Scientific Director, Kavli Neuroscience Discovery Institute, **John Hopkins University & School of Medicine**

10:20am

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-ups throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

10:50am **Presentation: Blending Digital Technologies in Clinical Trials**

Francesca Cormack, Director of Research & Innovation, **Cambridge Cognition**

11:15am **Wellness Break**

Get-up and have a stretch before the next session begins.

11:20am **Presentation: Next-Gen Solutions for Neuroscience Problems**

- A inside look at Genentech’s current neuroscience program
- How are Genentech bringing tech to biotech to tackle CNS disorders?
- How can you implement tech to modulate the most complex organ in the body?

Mikael Eliasson, Global Head of Innovation, Neuroscience, **Genentech**

11:45am **Wellness Break**

Get-up and have a stretch before the next session begins.

11:50am **Presentation: Developing Cutting-Edge Medical Technology for Neuroscience Innovation**

- An insight into leading Medtech efforts for Neuro-tech advancements
- Will neuro-technology be readily available over the next 5 years?
- What does the future hold for medtech in CNS?

Ryan Field, Chief Technology Officer, **Kernel**

12:15pm **Wellness Break**

Get-up and have a stretch before the next session begins.

12:20pm **Panel Discussion: What Needs to Happen to Kickstart the Resurgence of Pharma back into CNS for Increased Patient Care?**

- What caused pharma to withdraw from CNS therapeutic development and what's changed since then?
- Where have we seen success with pharmaceutical companies in CNS?
- What commercial strategy adaptations can be made to ensure there is an ROI in such an uncertain field?
- Can the utilization of digital health tech take traditional pharma to the frontline for CNS therapeutic R&D?
- Are we likely to see partnerships with pharma, Biotechs and digital health companies for CNS therapeutic development in the near future?
- Can the development of CNS specific clinical trials help accelerate potential drugs into the hands of the patients? - Changes in CNS Clinical Trial Design to Accelerate Drug Development
- Panelists, what is the likelihood that we see a resurgence of pharmaceutical companies into the CNS space as their mainstream efforts in the next 5 years?
- How do you reduce the cost, time to market, and make clinical studies more accessible and faster?

Mads Dalsgaard, SVP, Head of Experimental Medicine & Clinical Development, **Lundbeck**
Francesca Cormack, Director of Research & Innovation, **Cambridge Cognition**
Anish Shindore, Head of Neurotech & Open Innovation, **Biogen**

Day 1 of The CNS Leaders Forum includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Digital Solutions Showcase

2pm Presentation: **Using Linguistic Biomarkers to Identify and Monitor Cognitive Wellness**

- A look into utilizing voice tech to help Identify and Monitor CNS disorders
- An understanding of which biomarkers are identified and how these relate to cognitive disorders
- What is the future for vocal biomarkers in CNS patient care?

Liam Kaufman, Co-Founder & CEO, **Winterlight Labs**

2:25pm **Wellness Break**

Get-up and have a stretch before the next session begins.

2:30pm Presentation: **How Digital Health and Digital Therapeutics are Leading the Charge Against CNS Disorders**

- How have digital solutions enabled a resurgence of CNS Treatments available for patients?
- Are digital therapeutics enough or is a pairing with a traditional drug also required?
- What areas have we seen success using DTx for CNS treatments and will we ever see a digital 'Cure'?

Eddie Martucci, Co-Founder & CEO, **Akili Interactive**

2:55pm **Wellness Break**

Get-up and have a stretch before the next session begins.

3:00pm Panel Discussion: **The Impact of Digital Interventions for CNS Patient Intervention and Treatment**

- What impact have digital health solutions had on the prevention and treatment of CNS diseases?
- How can digital solutions help increase the efficacy of current and future traditional CNS therapies?
- Where have we seen success using digital solutions in treating more severe CNS disorders such as alzheimers, dementia and parkinsons?
- Are digital solutions optimised for diagnosis or prevention and what are the current efforts for a digital cure?
- Is the future of CNS patient treatment digital, traditional drugs or a combination of both?

Kim Baden-Kristensen, Co-Founder & CEO, **Brain+**

Ciara Clancy, Founder & CEO, **Beats Medical**

Kate Rosenbluth, Co-Founder & CSO, **Cala Health**

Brent Vaughan, Chief Executive Officer, **Cognito Therapeutics**

3:45pm **Wellness Break**

Get-up and have a stretch before the next session begins.

3:50pm

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-ups throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

4:15pm **Wellness Break**

Get-up and have a stretch before the next session begins.

4:20pm **Panel Discussion: How can the CNS Industry work Together for Future Patient Success?**

- What are the next big steps required to advance effective therapies into the hands of the patients?
- Where should our efforts be focused to help further the industry?
- How can we demonstrate value in CNS therapies to investors, payers and healthcare providers?
- What is the biggest challenge holding back the industry right now?
- What does the future of Patient care for CNS look like?

Christoph Koch, Chief Business Development Officer, **Neuraxpharm**

Adam Koppel, Managing Director, **Bain Capital**

5:05pm **Chairs Closing Remarks**

Magdalene Moran, President & Chief Scientific Officer, **Caraway Therapeutics**

End CNS Leaders Forum Day 1

Conference Day 2, Wednesday, 16th June

8:00am **Conference Platform Opens**

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

9:00am

Speed Networking

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-ups throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

9:30am **Chair’s Opening Remarks**

Magdalene Moran, President & Chief Scientific Officer, **Caraway Therapeutics**

9:35am **Panel Discussion: What are Investors Looking for when Investing into CNS Therapeutics Areas?**

- Are Investors actively looking into the CNS area for investment opportunities?
- What is preventing investors from pulling the trigger on CNS therapeutic investments?
- What evidence do investors need to see to prompt investment?

- Are digital solutions more likely to see investment than traditional therapies?
- Do investors believe we will see success in the near future for CNS therapeutics?

Lana Ghanem, Managing Director, **Hikma Ventures**

Pavan Choksi, Venture Partner, **Arkitekt Ventures**

Laurence Barker, Partner & Chief Business Officer, **Dementia Discovery Fund**

Stacie Weninger, President, **FBRI**

10:20am **Wellness Break**

Get-up and have a stretch before the next session begins.

Industry Insights

10:25am **Presentation: An Insight into Caraway Therapeutics**

- A deep dive into Caraway's current therapeutics efforts for treating CNS Disorders
- How are Caraway Therapeutics ensuring success in the CNS field?
- What's next for Caraway Therapeutics?

Magdalene Moran, President & Chief Scientific Officer, **Caraway Therapeutics**

10:50am **Wellness Break**

Get-up and have a stretch before the next session begins.

10:55am **Presentation: Deep Dive Case Study into Neuraxpharm**

- An insight into how Neuraxpharm are developing new CNS therapeutics while also enhancing current therapies already in the market

- How are Neuraxpharm ensuring success utilizing this business model?
- A deep-dive into the future of Neuraxpharm

Christoph Koch, Chief Business Development Officer, **Neuraxpharm**

11:20am **Wellness Break**

Get-up and have a stretch before the next session begins.

11:25am **Presentation: Treating Alzheimers using Non-Invasive Digital Neurostimulation - A Case Study**

- An insight into Cognito's digital tool for treating Alzheimers
- How does Cognito's breakthrough device help treat Alzheimers?
- What can we expect next from Cognito Therapeutics?

Brent Vaughan, Chief Executive Officer, **Cognito Therapeutics**

11:50am **Wellness Break**

Get-up and have a stretch before the next session begins.

11:55am **Panel Discussion: How can we Improve Frontline Care for CNS Patients?**

- How can we educate patients and care-givers to ensure they are familiar with potential therapies?
- How can we help re-educate health care professionals to aid in early diagnostics for CNS disorders?
- What interventions can we put into place to help assist patients further?
- Are we currently serving patients with CNS disorders enough?

Donna Walsh, Executive Director, **European Federation of Neurological Associations**

Sabrina Paganoni, Co-Director, **MGH Neurological Clinical Research Institute**

12:40pm **Chairs Closing Remarks**

Magdalene Moran, President & Chief Scientific Officer, **Caraway Therapeutics**

Close of CNS Leaders Forum 2021